MVR0 Stock Overview
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Medivir AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.22 |
| 52 Week High | kr0.69 |
| 52 Week Low | kr0.19 |
| Beta | -0.19 |
| 1 Month Change | -0.64% |
| 3 Month Change | -23.10% |
| 1 Year Change | -65.46% |
| 3 Year Change | -71.71% |
| 5 Year Change | -88.06% |
| Change since IPO | -99.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| MVR0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.3% | -3.1% | 1.8% |
| 1Y | -65.5% | -22.4% | 2.2% |
Return vs Industry: MVR0 underperformed the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: MVR0 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| MVR0 volatility | |
|---|---|
| MVR0 Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MVR0's share price has been volatile over the past 3 months.
Volatility Over Time: MVR0's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 10 | Jens Lindberg | www.medivir.com |
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma.
Medivir AB (publ) Fundamentals Summary
| MVR0 fundamental statistics | |
|---|---|
| Market cap | €26.73m |
| Earnings (TTM) | -€7.72m |
| Revenue (TTM) | €659.67k |
40.5x
P/S Ratio-3.5x
P/E RatioIs MVR0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MVR0 income statement (TTM) | |
|---|---|
| Revenue | kr7.63m |
| Cost of Revenue | kr68.87m |
| Gross Profit | -kr61.23m |
| Other Expenses | kr28.09m |
| Earnings | -kr89.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.80 |
| Gross Margin | -802.20% |
| Net Profit Margin | -1,170.21% |
| Debt/Equity Ratio | 0% |
How did MVR0 perform over the long term?
See historical performance and comparison